196 related articles for article (PubMed ID: 34381173)
61. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
[TBL] [Abstract][Full Text] [Related]
62. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
[TBL] [Abstract][Full Text] [Related]
63. Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients.
Spagnolo PA; Ramchandani VA; Schwandt ML; Zhang L; Blaine SK; Usala JM; Diamond KA; Phillips MJ; George DT; Momenan R; Heilig M
Alcohol Clin Exp Res; 2014 Dec; 38(12):3024-32. PubMed ID: 25581657
[TBL] [Abstract][Full Text] [Related]
64. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Edelman EJ; Moore BA; Holt SR; Hansen N; Kyriakides TC; Virata M; Brown ST; Justice AC; Bryant KJ; Fiellin DA; Fiellin LE
AIDS Behav; 2019 Jan; 23(1):211-221. PubMed ID: 30073637
[TBL] [Abstract][Full Text] [Related]
66. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
[TBL] [Abstract][Full Text] [Related]
67. Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
O'Malley SS; Todtenkopf MS; Du Y; Ehrich E; Silverman BL
Alcohol Clin Exp Res; 2018 Oct; 42(10):2011-2021. PubMed ID: 30055046
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
69. [Efficacy of naltrexone in the treatment of alcohol dependence disorder in women].
Ponce G; Sánchez-García J; Rubio G; Rodríguez-Jiménez R; Jiménez-Arriero MA; Palomo T
Actas Esp Psiquiatr; 2005; 33(1):13-8. PubMed ID: 15704026
[TBL] [Abstract][Full Text] [Related]
70. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
71. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D; Oroszi G; O'Malley S; Anton R
J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057
[TBL] [Abstract][Full Text] [Related]
72. Naltrexone for alcohol dependence: a randomized controlled trial.
Morris PL; Hopwood M; Whelan G; Gardiner J; Drummond E
Addiction; 2001 Nov; 96(11):1565-73. PubMed ID: 11784454
[TBL] [Abstract][Full Text] [Related]
73. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.
Foa EB; Yusko DA; McLean CP; Suvak MK; Bux DA; Oslin D; O'Brien CP; Imms P; Riggs DS; Volpicelli J
JAMA; 2013 Aug; 310(5):488-95. PubMed ID: 23925619
[TBL] [Abstract][Full Text] [Related]
74. Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
de Laat B; Nabulsi N; Huang Y; O'Malley SS; Froehlich JC; Morris ED; Krishnan-Sarin S
Mol Psychiatry; 2021 Sep; 26(9):5053-5060. PubMed ID: 32541931
[TBL] [Abstract][Full Text] [Related]
75. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
[TBL] [Abstract][Full Text] [Related]
76. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
[TBL] [Abstract][Full Text] [Related]
77. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.
Fridberg DJ; Cao D; Grant JE; King AC
Alcohol Clin Exp Res; 2014 Oct; 38(10):2622-9. PubMed ID: 25335648
[TBL] [Abstract][Full Text] [Related]
78. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
Sluiter RL; Kievit W; van der Wilt GJ; Schene AH; Teichert M; Coenen MJH; Schellekens A
Eur Addict Res; 2018; 24(5):245-254. PubMed ID: 30384381
[TBL] [Abstract][Full Text] [Related]
79. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review.
Kedia SK; Ahuja N; Dillon PJ; Jones A; Kumar S; Satapathy S
J Psychoactive Drugs; 2023; 55(2):233-245. PubMed ID: 35635191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
